Mounjaro on the NHS from June 2025: the reality behind the headline

The myth: Mounjaro became freely available on the NHS in June 2025

The headline that ran through mid-2025 (that Mounjaro was now available on the NHS) was technically true and practically misleading in equal measure. What NICE recommended in December 2024 (TA1026) was a staged commissioning model: start with the highest-need patients, then expand the eligible population in phases over several years. The June 2025 date marked the opening of that first, narrow phase.

To qualify from June 2025, you needed a BMI of 40 or above and at least four of five specific conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. That combination describes a relatively small proportion of the population. If you had three conditions, or a BMI of 38, or sleep apnoea plus one other issue, you were outside Cohort 1. Many people who read about the rollout and assumed they'd now qualify found, on inquiry, that they didn't. That is not a failure of the policy; it reflects how phased commissioning works when a health service is introducing a high-cost treatment at scale.

The GP route, opened from April 2026 under the new QOF contract, adds another layer of nuance: GP practices can prescribe, but participation is optional, so access varies by area and practice. You can read more about how GP prescribing of Mounjaro under the NHS works and what to ask your practice.

What Cohort 2 changed, and what hasn't changed yet

The second cohort was activated on 23 June 2026, lowering the BMI threshold to 35–39.9 whilst keeping the requirement for four or more qualifying conditions. That matters because it brings in people who previously sat just below the BMI cutoff, but the four-condition requirement stays firm. Three conditions still aren't enough, and a BMI of 34 still doesn't qualify regardless of how many comorbidities are present.

Further phases are planned. Around March 2027, the qualifying combination is expected to reduce to three conditions at BMI 40 or above. Later phases will lower BMI thresholds and condition counts further, eventually reaching adults who have obesity without multiple comorbidities. The full timeline, criteria for each phase, and the ethnic-background BMI adjustments are covered in detail on the NHS Mounjaro eligibility criteria page.

One fact that doesn't change across any cohort: NHS patients must be enrolled in a structured wrap-around programme covering diet, physical activity and behavioural support. It is part of the treatment, not an optional add-on. If your GP's practice is not yet set up to offer that programme, access may be delayed even if you meet the clinical criteria on paper. NICE's appraisal of tirzepatide (TA1026) sets out the commissioning conditions in full.

If you don't qualify for the NHS rollout yet, here is what that actually means

The honest position: most people searching for Mounjaro on the NHS in June 2025 did not qualify under Cohort 1, and many still don't qualify under Cohort 2. That is frustrating, especially when the medicine is clinically licensed for a broader population than the NHS currently commissions it for.

The licensed eligibility for private prescription is meaningfully wider: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, can be considered following clinical assessment. That covers people who are years away from reaching a phased NHS cohort. For people in that gap, a private route through a regulated online pharmacy is the alternative. It is not a workaround; it is the legal, clinical route for those outside NHS criteria.

If you are exploring that option, the one thing worth checking before anything else is whether a pharmacy is GPhC-registered. You can verify the GPhC registration of nume's pharmacy (registration 9012878) directly on the regulator's website. For a broader look at how to get Mounjaro through a private online pharmacy safely, that page covers the process step by step, including identity and weight verification and what genuine clinical oversight looks like.

Cost is a reasonable question at this point. Since Eli Lilly raised the UK list price in September 2025, private Mounjaro prices have typically ranged from around £149 to £375 per month depending on dose and provider, context worth knowing before you start comparing services. If you are also considering tirzepatide from other providers, it is worth reading about whether Synedica tirzepatide is legitimate before making any decisions. The Mounjaro cost page explains what legitimate private pricing includes and what to watch for when a price looks unusually low.

One practical note on what happens once you do start treatment

Whether you access tirzepatide through the NHS or privately, the medicine itself is the same: a once-weekly subcutaneous injection, stored in the fridge between 2 and 8°C. Most people find it settles into routine quickly, the pen lives in the fridge door, same day each week, same as any other medication that needs refrigerating. The Patient Information Leaflet that comes with your prescription covers the exact storage window and what to do if the pen has been at room temperature.

Treatment starts at 2.5mg, the dose designed to let your body adjust rather than to produce weight loss immediately. The prescriber titrates from there, typically in four-week steps. Side effects are mostly gastrointestinal (nausea, loose stools, some reflux) and tend to settle as the body adapts, though they can be more noticeable after a dose increase. The NHS tirzepatide medicines page has a clear, patient-level overview of side effects and when to seek urgent help. If you have questions about the full picture of treatment, the Mounjaro treatment overview covers everything from how it works to what clinical trials found.

If you'd like a prescriber to assess whether you're suitable for treatment now, rather than waiting to see which NHS cohort you might eventually reach, you can check your eligibility with a free consultation, reviewed the same day by a real clinician, not a queue for software.